Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,835 questions · 1,886 findings · 74 reviews · Skin

No studies found 542 · 28.7%GRADE not reported 130 · 6.9%Very low 326 · 17.3%Low 434 · 23%Moderate 348 · 18.5%High 106 · 5.6%

Etanercept vs placebo

Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Ustekinumab vs placebo

Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Ustekinumab vs placebo

Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Ustekinumab vs placebo

Proportion of participants achieving a 50% reduction in disease severity · chronic palmoplantar pustulosis

Ustekinumab showed no clear difference in proportion of participants achieving a 50% reduction in disease… compared with placebo (low certainty).

1 finding from 1 review

Ustekinumab vs placebo

Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Guselkumab vs placebo

Proportion of participants cleared or almost cleared ‐ not reported · chronic palmoplantar pustulosis

It is very uncertain whether guselkumab changes proportion of participants cleared or almost cleared compared with placebo (very low certainty).

1 finding from 1 review

Guselkumab vs placebo

Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis

Guselkumab showed no clear difference in proportion of participants with adverse effects serious or severe… compared with placebo (low certainty).

1 finding from 1 review

Guselkumab vs placebo

Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Guselkumab vs placebo

Proportion of participants achieving a 50% reduction in disease severity · chronic palmoplantar pustulosis

Guselkumab probably leads to higher proportion of participants achieving a 50% reduction in disease… compared with placebo (moderate certainty).

1 finding from 1 review

Guselkumab vs placebo

Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Secukinumab vs placebo

Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis

Secukinumab probably leads to higher proportion of participants with adverse effects serious or severe… compared with placebo (moderate certainty).

1 finding from 1 review